A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2018
At a glance
- Drugs FAZ 053 (Primary) ; Spartalizumab (Primary)
- Indications Breast cancer; Endometrial cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 18 Jun 2018 Planned number of patients changed from 315 to 212.
- 18 Jun 2018 Planned End Date changed from 6 Oct 2019 to 28 Feb 2020.
- 18 Jun 2018 Planned primary completion date changed from 6 Oct 2019 to 28 Feb 2020.